Maraviroc administration is feasible in pediatric allogeneic transplant recipients

Maraviroc at a dose of ~300 mg/m² achieves acceptable plasma levels and functional blockade of chemokine receptor type 5

Maraviroc may be helpful in preventing acute visceral graft-versus-host disease in children with pre-existing enteropathy